Ms. A was a 29-year-old woman with bulimia nervosa who was enrolled in a clinical trial designed to evaluate naltrexone (100 mg/day) in the treatment of eating disorders. This patient had a family history of anxiety, but she had never suffered from any psychiatric disorder other than bulimia. Any accidental, medical, and/or recreational exposure to opiates was definitely ruled out. Before being enrolled in the study, the patient gave her written informed consent. She received 100 mg of naltrexone orally, and some hours later she experienced a state of alarm, demonstrating marked anxiety, chest discomfort, shortness of breath, profuse sweating, nausea, derealization, and fear of dying and of losing control. She was unable to stay at home alone or to go out without being accompanied. During the following 3 days she continued to take 100 mg of naltrexone as previously scheduled. However, the frequency of the panic attacks increased progressively, reaching a pattern of successive short bursts. On the fourth day, she came to the hospital in a state of alarm, manifesting fear of dying and of going crazy. She was treated with alprazolam (0.5 mg) and experienced partial relief of the symptoms. However, the day after, following a further dose of naltrexone, she experienced a relapse into bursts of panic attacks. Withdrawal of naltrexone led to complete remission of the panic symptoms in a couple of days. Since then, she has never experienced panic episodes.